GLP-1 medicines for weight loss
semaglutide · tirzepatide · liraglutide · 'weight-loss injections' · 'the Ozempic jab'
Weight-loss injections have moved from diabetes clinics to dinner-party conversation in three years, and Singapore searches for 'semaglutide' and 'weight loss injection' now outnumber searches for most clinic devices. The questions people ask are about how much weight comes off, what happens to the face, and what happens when you stop.
Search interest: about 500 searches a month in Singapore for “glp 1 weight loss” (Ahrefs, October 2026).
The weight loss is real and well measured; so is the regain when it stops. The face it leaves behind is a separate decision, better made once the weight has settled.
Reviewed against the Aesthetics International standard. Category: Conditions.
Do GLP-1 weight-loss injections work?
Established. The weight loss is real and well measured; so is the regain when it stops. The face it leaves behind is a separate decision, better made once the weight has settled. The evidence is unusually strong for an aesthetic-adjacent treatment.
- Verdict
- Established Long clinical track record. Results depend on selection and technique more than on the device.
- Evidence base
- 5 PubMed-indexed studies cited below, including systematic reviews, randomised trials.
- Suits
- Adults who meet the medical criteria for weight management treatment, prescribed and monitored by a doctor, who understand that the medicine is continued rather than completed and that eating and activity still matter.
- Not for
- Anyone seeking to lose a few kilograms for an event, people with a history of certain thyroid or pancreatic conditions, pregnancy, and anyone buying injections online or from a non-medical source.
- In Singapore
- Semaglutide and tirzepatide are prescription-only medicines in Singapore, registered with the HSA, and are prescribed after a medical assessment that includes weight history, medical conditions and blood tests.
- Category
- Conditions · about 500 searches a month in Singapore for “glp 1 weight loss”
- Reviewed
- 6 October 2026 by Aesthetics International. Revised as evidence and regulation change.
What it is
GLP-1 receptor agonists are prescription medicines, given as a weekly or daily injection, that mimic a gut hormone to slow stomach emptying and reduce appetite. Semaglutide and liraglutide act on the GLP-1 receptor alone; tirzepatide acts on GLP-1 and GIP receptors together. They were developed for type 2 diabetes and are now approved, at higher doses, for weight management in adults with obesity or with overweight and a weight-related condition.
How it works
Appetite falls, meals end sooner and food noise quietens, so energy intake drops without conscious restriction. The dose is stepped up over several months to limit nausea. Weight loss continues for roughly a year and then plateaus; the effect depends on continued dosing, which is the most important fact about the class.
What the evidence says
The evidence is unusually strong for an aesthetic-adjacent treatment. In the 68-week STEP 1 trial, semaglutide 2.4 mg produced a mean weight loss of about 15 per cent against 2.4 per cent with placebo; in SURMOUNT-1, tirzepatide produced 15 to 21 per cent depending on dose. A 2024 meta-analysis in people without diabetes confirmed the size and consistency of the effect. The same literature is clear about the limits: in the STEP 1 extension, participants regained about two-thirds of the lost weight within a year of stopping, and gastrointestinal side effects are common during dose escalation. Loss of facial fat with rapid weight loss — the 'Ozempic face' — is real and is reviewed separately.
What people are saying
Paraphrased from public discussion on TikTok, Instagram, Reddit and in the press. Not testimonials, and not about any one clinic. Reported in: reddit.com, straitstimes.com.
What the studies show
- RCT
In 1,961 adults without diabetes, semaglutide 2.4 mg weekly produced a mean weight change of −14.9% at 68 weeks against −2.4% with placebo; 86% of the treatment group lost at least 5% of body weight.
Once-Weekly Semaglutide in Adults with Overweight or Obesity. — N Engl J Med, 2021. PMID 33567185.
- RCT
Across 2,539 participants, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg tirzepatide against −3.1% with placebo; gastrointestinal events were the commonest adverse effects.
Tirzepatide Once Weekly for the Treatment of Obesity. — N Engl J Med, 2022. PMID 35658024.
- RCT extension
One year after semaglutide was withdrawn, participants had regained two-thirds of the weight they had lost, and most cardiometabolic improvements reverted towards baseline.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. — Diabetes Obes Metab, 2022. PMID 35441470.
- systematic review
Pooled trials in adults without diabetes showed a consistent, clinically significant reduction in body weight with semaglutide, with gastrointestinal adverse events the main tolerability issue.
Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus: A systematic review and meta-analysis. — Obes Rev, 2024. PMID 38923272.
- systematic review
Rapid GLP-1-mediated weight loss is associated with loss of facial fat volume and skin laxity, with implications for how and when facial treatments are planned.
"Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss. — Aesthet Surg J Open Forum, 2025. PMID 40626110.
Studies are selected for relevance and quality, not for agreement with the verdict; PubMed records are linked so the reader can check them.
Who it suits
Suits
Adults who meet the medical criteria for weight management treatment, prescribed and monitored by a doctor, who understand that the medicine is continued rather than completed and that eating and activity still matter.
Not for
Anyone seeking to lose a few kilograms for an event, people with a history of certain thyroid or pancreatic conditions, pregnancy, and anyone buying injections online or from a non-medical source.
Alternatives
The two reviewed treatments most often weighed against GLP-1 medicines for weight loss, on the same standard.
| GLP-1 medicines for weight loss | Fat freezing | FaceTite and BodyTite | |
|---|---|---|---|
| Verdict | Established | Established | Established |
| What it is | GLP-1 receptor agonists are prescription medicines, given as a weekly or daily injection, that mimic a gut hormone to slow stomach emptying and reduce appetite. | A suction cup cools a pinched fold of fat to a temperature that triggers fat-cell death while sparing skin and nerves. | InMode's radiofrequency-assisted lipolysis (RFAL) systems pass a thin internal probe under the skin and an external electrode over it; radiofrequency energy flows between them, melting fat and heating the underside of the dermis to a monitored temperature. |
| Evidence base | 5 PubMed-indexed studies cited below, including systematic reviews, randomised trials. | 3 PubMed-indexed studies cited below, including systematic reviews. | 4 PubMed-indexed studies cited below, including systematic reviews. |
| Suits | Adults who meet the medical criteria for weight management treatment, prescribed and monitored by a doctor, who understand that the medicine is continued rather than completed and that eating and activity still matter. | Discrete pinchable pockets — flanks, lower abdomen — in people with good skin recoil who want reduction, not definition. | Mild to moderate laxity of the jowls, neck, arms or abdomen with some fat to remove, in people who want more than non-invasive devices give and less than excisional surgery, under a surgeon experienced with the probe. |
| In one line | The weight loss is real and well measured; so is the regain when it stops. The face it leaves behind is a separate decision, better made once the weight has settled. | Reducing fat under skin that has already lost its recoil leaves the same outline and looser skin — settle which is dominant first. | 'Scarless' describes the incision, not the recovery or the risk, and it tightens skin without lifting what has descended. |
Risks
Nausea, vomiting, constipation and reflux during escalation; gallbladder problems; rare pancreatitis; loss of muscle alongside fat; loss of facial volume; weight regain on stopping. Counterfeit pens are a documented international problem.
In Singapore
Semaglutide and tirzepatide are prescription-only medicines in Singapore, registered with the HSA, and are prescribed after a medical assessment that includes weight history, medical conditions and blood tests. They may not be advertised to the public, which is why compliant clinics do not name them in marketing; this review names them generically for information. Faces that lose volume quickly are a growing reason for aesthetic consultations, and are better planned once weight has stabilised.
“The weight loss is real and well measured; so is the regain when it stops. The face it leaves behind is a separate decision, better made once the weight has settled.”
Vetted protocols on the same problem
Questions
How much weight do GLP-1 injections take off?
What happens when you stop?
Does it cause 'Ozempic face'?
Can I get weight-loss injections in Singapore?
Is a microdose effective?
Is it an aesthetic treatment?
Cite this review
Aesthetics International (2026). GLP-1 medicines for weight loss: does it work? Evidence, risks and verdict. https://aesthetics-international.org/treatments/glp-1-weight-loss/ (reviewed 6 October 2026).
Editorial, unpaid and independent of any manufacturer. Verdict: Established. See what works and what doesn't across all 153 reviews. Spotted an error or a newer study? Suggest a correction — changes are logged on the corrections page. Terms are defined in the glossary.
Where this review is used
Have a question about this treatment?
Ask us — or ask to be matched with a practitioner in Singapore who follows evidence-based treatment. Whether it is right for you is decided at an in-person assessment, not by a review; sometimes the answer is a different treatment, or none.
WhatsApp +65 8023 7170Suggest a treatment to review
Physicians, manufacturers and readers can propose a treatment for review. Reviews are editorial and are not paid for.
[email protected]